The 36-month beta value for TSHA is at 0.34. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TSHA is 128.62M, and currently, shorts hold a 12.49% of that float. The average trading volume for TSHA on May 09, 2024 was 2.84M shares.
TSHA) stock’s latest price update
Taysha Gene Therapies Inc (NASDAQ: TSHA)’s stock price has decreased by -4.03 compared to its previous closing price of 2.48. However, the company has seen a -1.65% decrease in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-05-07 that DALLAS, May 07, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024, and host a corporate update conference call and webcast on Tuesday, May 14, 2024, at 4:30 PM Eastern Time.
TSHA’s Market Performance
TSHA’s stock has fallen by -1.65% in the past week, with a monthly drop of -19.59% and a quarterly rise of 54.55%. The volatility ratio for the week is 8.40% while the volatility levels for the last 30 days are 9.41% for Taysha Gene Therapies Inc The simple moving average for the last 20 days is -7.11% for TSHA stock, with a simple moving average of 10.34% for the last 200 days.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with Piper Sandler repeating the rating for TSHA by listing it as a “Overweight.” The predicted price for TSHA in the upcoming period, according to Piper Sandler is $9 based on the research report published on April 09, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $1.50, previously predicting the price at $14. The rating they have provided for TSHA stocks is “Hold” according to the report published on February 01st, 2023.
Morgan Stanley gave a rating of “Equal-Weight” to TSHA, setting the target price at $3 in the report published on January 27th of the previous year.
TSHA Trading at -10.31% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.82% of loss for the given period.
Volatility was left at 9.41%, however, over the last 30 days, the volatility rate increased by 8.40%, as shares sank -24.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.86% lower at present.
During the last 5 trading sessions, TSHA fell by -1.65%, which changed the moving average for the period of 200-days by +255.33% in comparison to the 20-day moving average, which settled at $2.52. In addition, Taysha Gene Therapies Inc saw 34.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 100,000 shares at the price of $1.63 back on Nov 17 ’23. After this action, Manning Paul B now owns 16,566,667 shares of Taysha Gene Therapies Inc, valued at $163,000 using the latest closing price.
Alam Kamran, the Chief Financial Officer of Taysha Gene Therapies Inc, sale 33,000 shares at $2.33 during a trade that took place back on Aug 24 ’23, which means that Alam Kamran is holding 258,042 shares at $76,890 based on the most recent closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -4.66 for the present operating margin
- 0.87 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -7.38. The total capital return value is set at -0.31. Equity return is now at value -294.04, with -56.40 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -35.01.
Currently, EBITDA for the company is -70.0 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 23.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.06.
Conclusion
In conclusion, Taysha Gene Therapies Inc (TSHA) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
